Johnson & Johnson, Stroke and Cerenovus
Johnson & Johnson halts late-stage E.coli vaccine trial
NASCAR, Jimmie Johnson
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...
Johnson & Johnson has launched the TECNIS PureSee™ intraocular lens in India, catering to individuals with presbyopia. The ...
A class action lawsuit launched in Auckland today questioning Johnson and Johnson cold and flu products follows similar suits ...
Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...
We recently published a list of 17 Best Stocks for Kids According to Jim Cramer. In this article, we are going to take a look ...
The lawsuit says Kiwis have been deceived for about two decades about an ingredient in cold and flu medicine.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results